{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:13:33Z","timestamp":1758039213754,"version":"3.44.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ad.2022.05.035","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T20:03:53Z","timestamp":1671480233000},"page":"363-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience"],"prefix":"10.1016","volume":"114","author":[{"given":"J.","family":"Arroyo-Andr\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Falkenhain-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Agud-Dios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rivera-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2022.05.035_bib0045","doi-asserted-by":"crossref","first-page":"e14584","DOI":"10.1111\/dth.14584","article-title":"Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience","volume":"34","author":"Bonifati","year":"2021","journal-title":"Dermatol Ther"},{"journal-title":"Actas Dermosifiliogr","year":"2021","author":"Carrascosa","key":"10.1016\/j.ad.2022.05.035_bib0050"},{"key":"10.1016\/j.ad.2022.05.035_bib0055","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s13555-021-00556-2","article-title":"Risankizumab for the treatment of moderate-to-severe psoriasis: Real-life multicenter experience from the Czech Republic","volume":"11","author":"Gkalpakiotis","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2022.05.035_bib0060","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3390\/jcm9072170","article-title":"Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study","volume":"9","author":"Galluzzo","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ad.2022.05.035_bib0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.05.035_bib0070","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/jdv.16521","article-title":"Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies","volume":"34","author":"Strober","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.05.035_bib0075","doi-asserted-by":"crossref","first-page":"e14144","DOI":"10.1111\/dth.14144","article-title":"Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12\/23 and\/or anti IL-23: preliminary data of a real-life 16-week retrospective study","volume":"33","author":"Megna","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2022.05.035_bib0080","first-page":"1","article-title":"Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study","author":"Megna","year":"2022","journal-title":"J Dermatol Treat"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731022010547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731022010547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:14:34Z","timestamp":1757553274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731022010547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0001731022010547"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2022.05.035","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2022.05.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}